BLLN Stock Summary and Trading Ideas (Billiontoone - Class A | NASDAQ:BLLN)

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

Billiontoone - Class A trades on the NASDAQ stock market under the symbol BLLN.

As of September 4, 2026, BLLN stock price declined to $99.39 with 934,286 million shares trading.

BLLN has a beta of -0.17, meaning it tends to be less sensitive to market movements. BLLN has a correlation of 0.00 to the broad based SPY ETF.

BLLN has a market cap of $4.69 billion. This is considered a Mid Cap stock.

Last quarter Billiontoone - Class A reported $109 million in Revenue and $.15 earnings per share. This fell short of revenue expectation by $-8 million and missed earnings estimates by -$.09.

The top ETF exchange traded funds that BLLN belongs to (by Net Assets): VTI, VB, VBR, VBK, VXF.

BLLN support price is $96.25 and resistance is $102.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BLLN shares will trade within this expected range on the day.